Evidence map›Paper›PMID 36494816›Full record

ArticleJournal of nanobiotechnology2022

Gold nanoparticle delivery to solid tumors: a multiparametric study on particle size and the tumor microenvironment.

Mukaddes Izci, Christy Maksoudian, Filipa Gonçalves, Lucia Aversa, Robbe Salembier, Ara Sargsian, Irati Pérez Gilabert, Tianjiao Chu, Carla Rios Luci, Eduardo Bolea-Fernandez and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Mukaddes IzciNanoHealth and Optical Imaging Group, Department of Imaging and Pathology, KU Leuven, Herestraat 49, B3000, Louvain, Belgium.
Christy MaksoudianNanoHealth and Optical Imaging Group, Department of Imaging and Pathology, KU Leuven, Herestraat 49, B3000, Louvain, Belgium.
Filipa GonçalvesNanoHealth and Optical Imaging Group, Department of Imaging and Pathology, KU Leuven, Herestraat 49, B3000, Louvain, Belgium.
Lucia AversaNanoHealth and Optical Imaging Group, Department of Imaging and Pathology, KU Leuven, Herestraat 49, B3000, Louvain, Belgium.
Robbe SalembierNanoHealth and Optical Imaging Group, Department of Imaging and Pathology, KU Leuven, Herestraat 49, B3000, Louvain, Belgium.
Ara SargsianTranslational Cell and Tissue Research Unit, Department of Imaging and Pathology, KU Leuven, Herestraat 49, B3000, Louvain, Belgium.
Irati Pérez GilabertNanoHealth and Optical Imaging Group, Department of Imaging and Pathology, KU Leuven, Herestraat 49, B3000, Louvain, Belgium.
Tianjiao ChuNanoHealth and Optical Imaging Group, Department of Imaging and Pathology, KU Leuven, Herestraat 49, B3000, Louvain, Belgium.
Carla Rios LuciNanoHealth and Optical Imaging Group, Department of Imaging and Pathology, KU Leuven, Herestraat 49, B3000, Louvain, Belgium.
Eduardo Bolea-FernandezAtomic and Mass Spectrometry-A&MS Research Group, Department of Chemistry, Ghent University, Campus Sterre, Krijgslaan 281-S12, 9000, Ghent, Belgium.
David NittnerLaboratory for Molecular Cancer Biology, VIB-KU Leuven, Herestraat 49, B3000, Louvain, Belgium.
Frank VanhaeckeAtomic and Mass Spectrometry-A&MS Research Group, Department of Chemistry, Ghent University, Campus Sterre, Krijgslaan 281-S12, 9000, Ghent, Belgium.
Bella B ManshianTranslational Cell and Tissue Research Unit, Department of Imaging and Pathology, KU Leuven, Herestraat 49, B3000, Louvain, Belgium.
Stefaan J SoenenNanoHealth and Optical Imaging Group, Department of Imaging and Pathology, KU Leuven, Herestraat 49, B3000, Louvain, Belgium. s.soenen@kuleuven.be.
KU Leuven · BEGhent University · BEVIB-KU Leuven Center for Cancer Biology · BE

Funding

BOF CELSAChinese Government Scholarship CSCErasmus+ HORIZON Erasmus+Fonds Wetenschappelijk Onderzoek FWO-SBFonds Wetenschappelijk Onderzoek G0B2919NHORIZON EUROPE European Research Council 757398
6 · The paper itself

Abstract

Nanoparticle (NP) delivery to solid tumors remains an actively studied field, where several recent studies have shed new insights into the underlying mechanisms and the still overall poor efficacy. In the present study, Au NPs of different sizes were used as model systems to address this topic, where delivery of the systemically administered NPs to the tumor as a whole or to tumor cells specifically was examined in view of a broad range of tumor-associated parameters. Using non-invasive imaging combined with histology, immunohistochemistry, single-cell spatial RNA expression and image-based single cell cytometry revealed a size-dependent complex interaction of multiple parameters that promoted tumor and tumor-cell specific NP delivery. Interestingly, the data show that most NPs are sequestered by tumor-associated macrophages and cancer-associated fibroblasts, while only few NPs reach the actual tumor cells. While perfusion is important, leaky blood vessels were found not to promote NP delivery, but rather that delivery efficacy correlated with the maturity level of tumor-associated blood vessels. In line with recent studies, we found that the presence of specialized endothelial cells, expressing high levels of CD276 and Plvap promoted both tumor delivery and tumor cell-specific delivery of NPs. This study identifies several parameters that can be used to determine the suitability of NP delivery to the tumor region or to tumor cells specifically, and enables personalized approaches for maximal delivery of nanoformulations to the targeted tumor.

Indexed as

Metal NanoparticlesNanoparticlesNeoplasmsB7 AntigensCell Line, TumorDrug Delivery SystemsEndothelial CellsGoldHumansParticle SizeTumor MicroenvironmentB7 AntigensCD276 protein, humanGoldBiodistributionNanomedicineNanoparticlesOncologyTargeted delivery

Identifiers

PMID36494816
PMCPMC9733103
OpenAlexW4311665865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.